Synthesis, structure and in vitro cytotoxicity testing of some 1,3,4-oxadiazoline derivatives from 2-hydroxy-5-iodobenzoic acid

1,3,4-Oxadiazole Containing Compounds As Therapeutic Targets For Cancer Therapy

BACKGROUND

Cancer is the first or second leading cause of premature death in 134 of 183 countries in the world. 1,3,4-Oxadiazoles are five memebered heterocyclic rings containing two nitrogen (two atoms) and oxygen (one atom). They show better thermal stability, metabolic stability, aqueous solubility and lower lipophilicity than the other isomeric oxadiazoles. They are important class of heterocycles present in many drug structures like Raltegravir, Furamizole Tidazosin, Nesapidil, Setileuton (MK-0633) and Zibotentan. Presence of this nucleus in the therapeutics has made them an indispensable anchor for drug design and development. Several 1,3,4-oxadiazoles are prepared and reported as anticancer agents by numerous scientists worldwide.

OBJECTIVES

The present review discusses the anticancer potentials together with the molecular targets of 1,3,4-oxadiazoles reported since 2010. The structure activity relationship (SAR) and molecular docking simulation on different targets have also been discussed herein. Some of the important cancer targets have also been explored.

METHODS

The most potent 1,3,4-oxadiazoles reported in literature was highlighted in the manuscript. The anticancer activity was reported in terms of growth percent (GP), percent growth inhibition (%GI), GI50, IC50, and LC50 and TGI.

RESULTS

1,3,4-Oxadiazoles are an important heterocyclic scaffolds with broad spectrum biological activities. They may be either mono substituted or disubstituted and act as an indispensable anchor for drug design and discovery due to their thermal stability together with low lipophilicity. They exhibited anticancer potentials and showed the inhibitions of various cancer targets.

CONCLUSION

The discussion outlined herein will proved to be a helpful and vital tool for medicinal chemists investigating and working with 1,3,4-oxadiazoles and anticancer research programs.

Synthesis, structure and in vitro cytotoxicity testing of some 2-aroylbenzofuran-3-ols

Five 2-aroyl-5-bromobenzo[b]furan-3-ol compounds (two of which are new) and four new 2-aroyl-5-iodobenzo[b]furan-3-ol compounds were synthesized starting from salicylic acid. The compounds were characterized by mass spectrometry and ¹H NMR and ¹³C NMR spectroscopy. Single-crystal X-ray diffraction studies of four compounds, namely, (5-bromo-3-hydroxybenzofuran-2-yl)(4-fluorophenyl)methanone, C₁₅H₈BrFO₃, (5-bromo-3-hydroxybenzofuran-2-yl)(4-chlorophenyl)methanone, C₁₅H₈BrClO₃, (5-bromo-3-hydroxybenzofuran-2-yl)(4-bromophenyl)methanone, C₁₅H₈Br₂O₃, and (4-bromophenyl)(3-hydroxy-5-iodobenzofuran-2-yl)methanone, C₁₅H₈BrIO₃, were also carried out. The compounds were tested for their in vitro cytotoxicity on the four human cancer cell lines KB, Hep-G2, Lu-1 and MCF7. Six compounds show good inhibiting abilities on Hep-G2 cells, with IC₅₀ values of 1.39-8.03 µM.

Synthesis of a new series of 2-hydroxy-5-iodo-N'-(1-arylethylidene)benzohydrazides using a deep eutectic solvent as solvent/catalyst under sonication

We report here the preparation of 2-hydroxy-5-iodo-N'-(1-arylethylidene)benzohydrazide compounds in good to excellent yields (83-98%) within a short reaction time (10-15 min), through a clean and efficient procedure. Seventeen new compounds were synthesized and fully characterized by FT-IR, NMR, and HRMS. The deep eutectic solvent can be recovered easily by phase extraction and can be reused up to several times without any significant loss of catalytic activity. Additionally, the method has a wide substrate scope and provides an accessible route for the large-scale direct synthesis of 2-hydroxy-5-iodo-N'-(1-arylethylidene)benzohydrazides.